Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

 Warsaw, Poland – 5 December 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and participating key opinion leaders for its virtual R&D Day.

The webcast event will be hosted by Molecure on the 7^th December 2022 at 13.30 - 16.30 CET / 12.30 – 15.30 BST/ 7.30 – 10.30 ET.

The meeting is available here:

https://us06web.zoom.us/j/84261604213?pwd=QTlVZytQTWFUd3Y1N080R2hwWGZydz09

The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure’s pipeline programs.

Agenda topics:

13.30-15.30

• Molecure’s Vision, Strategy and Pipeline
• OATD-01, Molecure’s first in class chitinase inhibitor:
• Clinical evaluation in sarcoidosis and potential patient impact (Prof. Krenke)
• Landscape and therapy opportunity in sarcoidosis
• Clinical development plan
• Other opportunities in interstitial lung disease
• OATD-02, Molecure’s novel dual arginase inhibitor:
• Pre-clinical activity in a broad range of cancers
• State of oncology in Poland (Prof. Szczylik)
• Clinical development plan

15.30-15.40 Break

15.40-16.30

• Early-stage pipeline
• Deubiquitinating enzymes (DUBs) program including USP7 in oncology
• YKL40 in oncology
• University of Michigan collaboration in fibrosis
• mRNA platform

Key Opinion Leader Presenters:

• Prof. Rafal Krenke, Pulmonologist, Head of Department of Internal Medicine, Pulmonary Diseases & Allergy, Medical University of Warsaw
• Prof. Cezary Szczylik, Oncologist, Head of the Department of Clinical Oncology and Chemotherapy Europejskie Centrum Zdrowia (European Health Center) Otwock

Molecure S.A. Presenters:

• Dr Marcin Szumowski     - CEO, President of the Board
• Dr Zbigniew Zasłona       - VP Research Biology, Member of the Board
• Dr Samson Fung              - Chief Medical Officer
• Dr Nicolas Beuzen           - Director of Business Development and Licensing